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In the present study, we investigated the effects of SCSE on variety of systemic processes 
which contribute to general health and viability of human subjects. The experiments were 
conducted according to a double-blind protocol in which six healthy individuals were 
administered 250 mg/day SCSE for 14 days, while 4 were treated with placebo. Peripheral 
blood was collected before and after the treatment period. Samples were analyzed for levels of 
selected cells, enzymes or metabolites. Subjects received SCSE showed increases in the 
values of mean cell volume, serum transferrin, mean peroxidase index and representation of 
peripheral blood lymphocytes. On the other hand, decreases were observed in circulating 
neutrophils, and ferritin levels. Changes observed in the present study do not fit into a clear 
pattern that might yield additional in-depth understanding of SCSE-mediated alterations in 
physiologic responses. The most encouraging result of the present study is absence of any 
indication of toxicity by subjects consuming the extract. 
 










Ongoing nutritional studies have recently revealed powerful health-promoting 
properties in components of some plants, which until recently had remained obscure because 
they were not typically consumed as food by humans. A particularly fascinating example is 
the seed kernel of sour cherry (Prunus cerasus). The fruit is a major export of several nations, 
including Hungary; however, the seed is currently considered an agricultural by-product and 
discarded. Chemical analysis of the seed kernel by authors of the present investigation 
revealed that the solid flavonoid-rich fraction, comprising approximately 64–68% of the 
kernel contains several health-enhancing polyphenolic compunds such as catechins, stillbenes, 
and anthocyanidins. The remaining 32–36% is an oil fraction rich in tocopherols and related 
compounds, including tocotrienols, oleic acid and triglycerides (Bak, Lekli et al. 2010). 
Results of work with sour cherry seed extract (SCSE) include demonstrations that oral 
administration of seed kernel meal to animals strongly stabilizes healthy tissue homeostasis 
and suppresses ischemia-reperfusion (IR) injury by augmenting expression of heme 
oxygenase-1 (HO-1), a major endogenous cytoprotective enzyme (Szabo, Gallyas et al. 2004, 
Czompa, Gyongyosi et al. 2014).  
 
Administration of the extract to animals as a feed supplement is observed to prevent 
and counteract retinal and myocardial IR injury in rats (Szabo, Gallyas et al. 2004, Czompa, 
Gyongyosi et al. 2014). Powerful cardioprotective effects were noted in hypercholesteremic 
rabbits fed with seed kernel extract.  In these experiments extract-treated animals exhibited 
significantly improved cardiac function, diminished infarct size and  atherosclerotic plaque 
formation, along with other indicators of resistance to the hypercholesteremic condition by 
animals receiving sour cherry seed extract (Juhasz, Kertesz et al. 2013). Further evidence for 
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potential therapeutic benefit of SCSE components was provided by Mahmoud et al showing 
that sour cherry seed solid fraction suppressed LPS-mediated expansion of human T cells 
activated to express TNF-a to a greater degree in cells taken from human type 2 diabetics, 
than from cells contributed by healthy subjects (Mahmoud, Al-Awadhi et al. 2013). This is 
particularly significant since TNF-alpha is a major mediator of insulin resistance and 
dysregulated inflammation in type 2 diabetes (Hotamisligil, Shargill et al. 1993, Hotamisligil 
2006, Hooper and Hooper 2009). The toxicological evaluation of the seed extract, which 
showed that oral administration at dosages in the range of 200x therapeutic level, did not 
result in any adverse effects, as evidenced by studies of liver and kidney enzymatic functions 
and immunohistochemistry (Bak, Czompa et al. 2011). 
 
Protection of rat retinas and rabbit hearts by sour cherry seed kernel components, 
along with suppression of pro-inflammatory signaling by leukocytes from in human diabetics, 
all correlated strongly with extract-mediated induction of heme oxygenase-1 in the 
experimental models used for these studies (Szabo, Gallyas et al. 2004, Juhasz, Kertesz et al. 
2013, Mahmoud, Al-Awadhi et al. 2013) Heme oxygenases are an essential endogenous 
antioxidant defense, expressed ubiqutously by most tissues in a wide variety of life forms 
(Haines, Lekli et al. 2012).  
 
The present study evaluates the capacity of SCSE to affect a variety of systemic 
processes which contribute to general health and viability of human subjects.  The SCSE 
dosage administered to subjects during this initial phase of a comprehensive program of 
human trials was for safety reasons far below the dosage observed to exert therapeutic effects 
in animals (Szabo, Gallyas et al. 2004). A major objective in utilization of a subclinical dose 
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range was to observe data trends resulting from oral SCSE treatment, without attendant risk 








Participants in the present investigation included 10 healthy volunteers (4 males and 6 
females), recruited from the staff of University of Debrecen Health Science Center. 
Individuals were screened for eligibility according to the following inclusion and exclusion 
criteria. Inclusion criteria for participation include the following: healthy individuals of both 
genders in an age range of 18-65 years and in good health, with no major disease. The 
following individuals were excluded from the present study: (a) persons afflicted at the time 
of recruitment with ongoing acute or chronic disease; (b) persons with histories of acute or 
chronic disease severe enough to require hospitalization and/or use of prescription drugs 
within 3 months of screening for participation in the study; (c) organ transplant recipients; (d) 
chronic substance abusers; (e) individuals who exhibit positive allergic response to sour 
cherry seed extract; (f) convalescents of any trauma more recent than 3 months. Informed 
written consent was obtained from the subjects, and the study has been approved by the Ethics 
Committee of the University of Debrecen, Hungary. All experiments carried out were in 
compliance with the Declaration of Helsinki. Both the investigators and participants in this 
investigation were blinded with respect to whether each oral treatment contained SCSE or 
placebo. 
 
Test cohorts and treatments 
Subjects were randomized into a test group of 6 subjects, each of whom was 
administered 250 mg SCSE daily for 14 days; and a control group of 4 subjects sham-treated 
with placebo (sugar).    
 
Sour cherry seed extract    
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Sour cherry seeds were collected by Jonaco, Ltd. (Nyírtass, Hungary) from orchards in 
the locale of Nyírtass after harvesting and processing the fruit.  The seeds were dried, and the 
kernels removed from the external shell components. The kernels were then macerated into a 
paste with a consistency suitable for oral administration to humans. This material was 
encapsulated in gelatin caplets at the bioproduction manufacturing facility belonging to the 




Baseline data was taken from each participant, including:  age, body weight and 
height, body mass index (BMI), mid-abdominal circumference, body fat percentage and 
skeletal muscle percentage.  
Peripheral blood was collected at the baseline, before the first intake of SCSE or 
placebo, and at the end of the treatment period. Peripheral blood white blood cell count 
(WBC), red blood cell count (RBC), hemoglobin (Hgb), hematocrit (HCT), mean cell volume 
(MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration 
(MCHC), red cell distribution width  (RDW), platelet cell count (PLT), mean platelet volume 
(MPV), platelet distribution width (PDW), mean peroxidase index (MPXI), and ratios of 
lymphocytes, monocytes, neutrophils, eosinophils and basophils were evaluated using an 
Advia 2120 hematology analyzer (Siemens Medical Solutions Diagnostics Europe Limited, 
Dublin, Ireland). The Cobas 8000 modular analyzer series (Roche Diagnostics GmbH, 
Mannheim, Germany) was used to evaluate blood of participants for total bilirubin (tBil), 
conjugated bilirubin (kBil), high- and low density lipoprotein (HDL & LDL), triglycerides  
(TGL), alkaline phosphatase (AP), amylase (AM), lipase (LP), magnesium, c-reactive protein 
(CRP), iron, transferrin, ferritin, glutamic-oxaloacetic transaminase (GOT), glutamic pyruvic 
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transaminase (GPT), and lactate dehydrogenase (LDH). The aforementioned analyses were 
conducted at the Department of Laboratory Medicine, University of Debrecen.   Plasma levels 
of HO-1 protein were determined at the Food Analytical Laboratory of University of 
Debrecen by using the StressXpressTM Human HO-1 ELISA Kit (Enzo Life Sciences 
International, Inc., Plymouth Meeting, Pennsylvania, USA). Briefly, plasma from each 
participant was incubated in 96-well microtiter plate coated with an antihuman HO-1 
antibody, followed by treatment with secondary/detect antibody and related reagents provided 
with kits. Plasma HO-1 levels were evaluated during the absorbance of the developed kit 
reagents at 450 nm in a Biotek ELX 808 Microplate Reader. Results are reported in 
nanograms (ng) of HO-1 protein per ml of plasma as median values of each of 4 ELISA 
outcomes (quadruplicates) within the designated interquartile range (IR) for the Enzo kits 
used to accomplish these HO-1 assays.  
 
Statistical analyses 
The SPSS ver. 20.0 (SPSS Inc., Chicago, IL, UDA) was used for statistical analysis. 
To assess the distribution of the data Kolgomorov-Smirnov test was used. In cases of normal 
distribution, we determined mean ± standard deviation (SD) values and used two-sample t test 
for statistical comparison of the experimental data. In cases of distributions different from that 
of normal, median, minimum and maximum values were calculated, and Mann-Whitney test 
was used. According to the distribution, Paired samples t test or Wilcoxon test was used to 
evaluate the changes in distinctive parameters. Differences were considered statistically 







Assessment of peripheral blood tests  
Demographic data and results of biometric measurements are shown in Table 1. As 
shown in Table 2, relative to control participants not administered SCSE, subjects treated with 
the extract exhibited small but significant increases in the values of mean cell volume (MCV) 
(p=0.024), serum transferrin (p=0.035), mean peroxidase index (MPXI) (p=0.015) and 
representation of peripheral blood lymphocytes (p=0.016). Table 2 also shows outcome 
variables significantly decreased in SCSE-treated participants relative to placebo-treated 
control subjects. These outcomes included decreases observed in circulating neutrophils 
(p=0.019), and ferritin (p=0.039). The significant changes in outcome variables were 
observed to occur only in the SCSE-treated subjects and not in placebo-treated participants.  
Ferritin levels of the two patients group could not be statistically compared, since the normal 
ranges of serum ferritin significantly differ between females and males. 
  
Plasma levels of HO-1 protein 
 Time course evaluation of plasma HO-1 levels is shown in Figure 1. Comparison of 
baseline plasma HO-1 concentration with measurements taken at 1- and 2 weeks post-
treatment demonstrates that SCSE at the dosage provided had no significant effects on 
systemic HO-1 levels. 
 
DISCUSSION 
The present study, in which SCSE was administered to human volunteers at dosages 
substantially below the dose range observed to result in clinical effects in animals (Szabo, 
Gallyas et al. 2004, Bak, Lekli et al. 2010, Juhasz, Kertesz et al. 2013, Czompa, Gyongyosi et 
al. 2014) was structured to meet three major criteria: First, a panel of 32 hematological, 
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serological and blood chemistry assays were selected as basic screening measures for effect of 
SCSE consumption, that encompassed a broad range of physiological activities known to be 
affected by disease. Utilization of highly automated testing for such a widely cast net allowed 
cost-effective assessment of multiple bioparameters that might be altered by the effect of the 
product. To best focus the present report on major outcomes of highest clinical relevance, 
only biomarkers that exhibited statistically significant changes as a result of SCSE oral 
treatment were displayed in the tables. Secondly, since these experiments constituted the first 
evaluation of orally delivered SCSE in humans, it was important to configure the 
investigation to avoid toxic effects, while nevertheless producing outcomes useful in 
predicting applications of the extract in preventive medicine and therapy. Third, although it 
was expected that use of substantially subclinical dosages of the extract would fail to produce 
dramatic changes in the parameters measured, the authors nevertheless anticipated that the 
dose range used would result in data trends expected to become more pronounced at dosages 
in the therapeutic range. 
 
Outcomes of the present study were considered not suitable as the basis for broad 
generalizations concerning the biological effects of SCSE, since only a small and 
heterogeneous group of human subjects participated. It must nevertheless be emphasized that 
the main purpose of this work was not in-depth characterization of the material, instead, a 
wide range of physiologic responses were screened for response trends that may indicate 
potentially toxic response to the product. Although the sample n for each assay was small, 
statistically valid (p<0.05) conclusions regarding SCSE effect on increase or decrease of a 
particular parameter may be made by comparison of persons receiving extract versus placebo, 




Previous studies have demonstrated that SCSE affects disease-associated hematologic 
and immune outcomes through increased HO-1 activation. Thus, analysis of the results of the 
present study focused on likely effects of this enzyme. It is nevertheless important to qualify 
the significant changes in hematologic and immune parameters by emphasizing that although 
these are clearly SCSE-associated, there is insufficient data shown here to ascribe these 
aforementioned effects to SCSE-induced changes in HO-1 activity since the experiment does 
not control for this variable by observing whether specifically inhibiting HO-1 activity also 
inhibits the observed response. Moreover, since consumption of the extract failed to result in 
significantly increased plasma levels of the enzyme, no conclusions can be made based on the 
present data about the correlation between HO-1 activity and the hematologic and immune 
effects. 
 
Outcome measures significantly increased following SCSE treatment. 
Significant increases were observed in mean cell volume (MCV), transferrin, Mean 
peroxidase index (MPXI) and Lymphocyte percentage (LYMP %) in subjects administered 
SCSE, with no corresponding significant change in untreated (control) subjects. Possible 
contributors to these increases are discussed below. 
MCV is a measure of the average red blood cell volume that is reported as part of a 
standard complete blood count. The normal reference range is typically 80-100 femtoliters 
(fL). The significant increase in this variable noted following SCSE treatment may be due to 
an effect of one or more components of the extract on differentiation of erythroid precursors 
in the bone marrow in ways which contribute to increase in red blood cell volume. 
Transferrins are iron-binding blood glycoproteins that control the level of free iron in 
biological fluids. Normal reference ranges for transferrin are 2.04–3.60 g/L. Significant 
increases in serum transferrin observed in SCSE-treated subjects may be related to MCV 
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levels based on the capacity of transferrin proteins to facilitate delivery of iron to erythroid 
progenitors of red blood cells via the transferrin receptor (Macedo and de Sousa 2008). A 
mechanism for modulation of this process is suggested by results of a recent study 
demonstrating that sustained induction of HO-1 decreased TR expression, along with several 
corollary alterations in cellular processing of iron (Li, Lonn et al. 2012). It is therefore 
possible that the slight increase in transferrin observed in the present study may be an 
adaptive response to maintain constant cellular iron intake levels due to decreased TR 
availability as a result of HO-1 induction due to SCSE intake. 
MPXI, which is a measure of neutrophil peroxidase activity, is observed to be 
decreased in persons afflicted with iron deficiency-associated anemia and increased as a result 
of iron replacement indicating the contribution of normal peroxidase activity to healthy iron 
metabolism. The reference range for this parameter is -10 to +10 arbitrary units (Gulley, 
Bentley et al. 1990). The positive correlation of MPXI with SCSE treatment may be unrelated 
to induction of HO-1 by the extract since it has been shown that HO-1 suppresses 
myeloperoxidase activity as a major feature of its capacity to ameliorate inflammatory tissue 
damage (Lin, Lai et al. 2013). The effect noted may alternatively be a consequence of 
immunogenicity by plant lectins in the extract (Moreira Rde, Ainouz et al. 1991), an effect 
that may also account for elevation in lymphocyte representation described below. It is also 
possible that SCSE-mediated upregulation of transferrin levels and MCV altered iron 
metabolism in ways that are reflected by increased myeloperoxidase activity and elevated 
MPXI.  
Peripheral blood lymphocytes, which include T, B and natural killer cells (NK cells) 
act as major mediators of immune activity, coordinating primary and antigen driven immune 
responses and antitumor functions (Charles A Janeway, Paul Travers et al. 2001). In normal 
healthy humans, the percentage representation of these cells ranges from ~16-45% of the total 
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white blood cell component. Proliferation of lymphocytes occurring in response to viral or 
bacterial infections, autoimmunity and cancer is unlikely to account for the very minor 
increase in this parameter observed in SCSE-treated participants. The increase in percentage 
of circulating lymphocytes noted in the present study, although significant (0.016) was minor 
in magnitude and probably not related to induction of heme oxygenase as a result of the SCSE 
treatment. Indeed, the anti-inflammatory effects of the extract were more likely to have 
stabilized lymphocyte count than elevated it based on the increased immunogenicity conferred 
on tissues by inflammatory processes (Charles A Janeway, Paul Travers et al. 2001). Other 
possible explanations for this observation is that SCSE may contain a meyloperoxidase 
inducer, possibly a plant lectin, which are strongly immunogenic carbohydrate-binding 
proteins produced by a wide variety of plants (Moreira Rde, Ainouz et al. 1991). These 
possibilities are nevertheless speculative and await more detailed studies for resolution. 
 
Outcome measures significantly decreased following SCSE treatment. 
Circulating neutrophil percentage (NEUT %) and ferritin were observed to 
significantly decrease in subjects administered SCSE, with no corresponding significant 
change in untreated (control) subjects. Neutrophils, which are the most frequently occuring 
white blood cell, serving as a first line of defense against microbial invaders (Witko-Sarsat, 
Rieu et al. 2000). Once activated, these cells contribute substantially to oxidative stress placed 
on tissues incidental to their antimicrobial function (Khansari, Shakiba et al. 2009). Reference 
range in peripheral blood: 35%-80%. The observed decrease in peripheral blood 
representation of these cells with SCSE treatment is consistent with observations that 
upregulation of endogenous antioxidants, including heme oxygenase, suppresses 
inflammatory tissue damage through mechanisms that include decreased numbers and activity 
of neutrophils (Guo and Ward 2007). Ferritin is a widely distributed protein which complexes 
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with iron and releases it in response to physiologic cues, serving as a reserve store of iron for 
an organism (Granier, Langlois d'Estaintot et al. 2003). The level of ferritin in blood and other 
fluids therefore reflects the quantity of iron available for maintenance of normal homeostatic 
functions (Theil 1987). Moreover, iron acts as an inducer for ferritin production to maintain 
levels of the protein sufficient to keep pace with iron storage requirements (Andrews, Arosio 
et al. 1992). HO-1 metabolizes heme and releases ferrous iron (Fe
2+
), which is an inducer of 
ferritin (Grochot-Przeczek, Dulak et al. 2012). The significant decrease in levels of this 
metabolite observed in response to SCSE treatment may be a consequence of HO-1 induction 
by the extract, which, despite the non-significant changes in its activity, may have occurred at 
levels sufficient to account for the small decrease in ferritin levels. Outcomes of the present 
study demonstrate SCSE treatment-associated changes in bioparameters that might reflect 
protective properties of the extract in cells or animals subjected to pathological stress as part 
of the experimental design.   Indeed, this flavonoid-rich extract has demonstrated powerful 
protective properties in previous studies.   It should nevertheless be emphasized that the 
subjects of this study were healthy and this investigation was undertaken primarily to assess 




The significantly altered parameters observed in blood of SCSE-treated subjects but 
not in untreated controls may or may not be related to induction of HO-1 expression by the 
extract. Sufficient data to support or refute such a possibility has not been produced in this 
study and the lack of significant HO-1 induction by the SCSE dosage administered, makes 
any correlations of this kind highly speculative. Moreover, the changes observed in the 
present study do not fit into a clear pattern that might yield additional in-depth understanding 
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of SCSE-mediated alterations in physiologic responses, although some of the results suggest 
that the extract is affecting iron metabolism at some – which in turn might be related to HO-1 
activity based on the known properties of the enzyme (Li, Lonn et al. 2012). The most 
encouraging result of the present study is absence of any indication of toxicity by subjects 
consuming the extract. Gross toxic effects were not expected based on animal studies 
conducted by the authors demonstrating non-toxicity of the extracts at dosages in the range of 
200x therapeutic (Bak, Czompa et al. 2011). It is very encouraging to note that subjects 
administered the extract exhibited no increases in the activity of glutamic-oxaloacetic 
transaminase (GOT) and glutamic pyruvic transaminase (GPT) which are liver function 
biomarkers used as indicators of drug toxicity (Atasoy, Erdogan et al. 2007), nor were any 
significant changes in the activity of plasma lactate dehydrogenase (LDH), which is an 
indicator of disrupted tissue homeostasis used for evaluation of herbal preparation safety 
profiles (Liu, Liu et al. 2013). Finally, a major objective of the efforts to determine the full 
scope of healthcare, cosmetic and dietary uses for SCSE is establishment of a solid safety 
profile as a necessary precondition for its human use. Previous studies have yielded very 
encouraging results. For example, no known toxicants were identified in chemical analysis of 
the seed kernel components (Bak, Lekli et al. 2010), moreover sustained high dose oral 
administration of SCSE failed to result in liver or kidney toxicity (Bak, Czompa et al. 2011). 
Ongoing efforts to gain an in-depth understanding of the effects of this substance, include 
experiments described in the present report; and a phase I clinical trial of SCSE delivered 
transdermally to osteoarthritic patients. This treatment resulted in significant systemic 
amelioration of multiple disease parameters (including joint pain) and augmented protective T 
lymphocyte activity, with no associated toxicity (Mahmoud, Haines et al. 2014). These 
outcomes and ongoing results of work-in-progress suggest that SCSE will be safe and 
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receiving placebo  
(n=4) 
P values 
Age (years) 38.17 ± 2.48 45.50 ± 6.81 p < 0.05 
Female/male 2/4 4/0  
Body weight (kg) 86.50 ± 12.34 87.50 ± 5.00 n.s. 
Height (cm) 174.67 ± 5.79 163.25 ± 5.12 p < 0.05 
Body mass index (BMI) 28.92 ± 5.454 25.42 ± 6.54 n.s. 
Belly circumference (cm) 100.17 ± 12.79 87.00 ± 12.62 n.s. 
Body fat (percentage by 
weight) 
31.50 ± 5.36 37.55 ± 10.26 n.s. 
Skeletal muscle (percentage 
by weight) 
32.53 ± 4.86 25.68 ± 3.51 p < 0.05 
 
Table 1. Demographical data and biometric measurements of test and control 
participants. Each bioparameter shown below was assessed at outset of study, prior to 







Test subjects SCSE 







Mean cell volume (MCV, fL) 
before 90.00 ± 3.54 91.30 ± 2.44 0.543 
after 90.87 ± 3.68 91.70 ± 3.49 0.730 
p value 0.024 0.675  
Transferrin (g/L) 
before 2.70 ± 0.27 2.73 ± 0.22 0.871 
after 2.84 ± 0.22 2.92 ± 0.39 0.697 
p value 0.035 0.188  
Mean peroxidase index 
(MPXI, arbitrary units) 
before -9.25 ± 15.81 -4.10 ± 6.21 0.558 
after -7.87 ± 15.49 -4.40 ± 6.79 0.689 
p value 0.015 0.682  
Peripheral blood lymphocytes 
(LYMPH, %) 
before 24.33 ± 5.66 28.55 ± 8.89 0.381 
after 29.08 ± 5.08 29.40 ± 12.01 0.955 
p value 0.016 0.734  
Peripheral blood neutrophils 
(NEUT, %) 
before 65.67 ± 7.30 60.78 ± 8.57 0.360 
after 59.17 ± 6.92 61.22 ± 12.37 0.742 
p value 0.019 0.866  
Ferritin (mg/L) 
before 176.05 ± 123.99 38.95 ± 23.45 N/A 
after 154.73 ± 111.36 35.25 ± 23.95 N/A 
p value 0.039 0.238  
 
Table 2. Outcome variables exhibiting significant changes following oral administration 
of sour cherry extract. Relative to control participants not administered SCSE, subjects 
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treated with the extract exhibited small but significant increases in the values of MCV, 
transferrin, MPXI and representation of peripheral blood lymphocytes. Relative to control 
participants not administered SCSE, subjects treated with the extract exhibited small but 
significant decreases in the values of circulating neutrophils and ferritin.  These changes in 
outcome variables were observed to occur only in the SCSE-treated subjects and not in 






Figure 1. Plasma heme oxygenase-1 (HO-1) levels. Plasma from SCSE-treated test subjects 
(n=6) and untreated control participants (n = 4) was evaluated for concentration of HO-1 
protein using the StressXpressTM Human HO-1 ELISA Kit before SCSE treatment 
(baseline), 1 week and 2 weeks following administration of extract. Bars show the mean and 
the standard deviation (SD). No significant effects noted.   
 
